Aurobindo Pharma Ltd.

₹1,668.4

-30.5 (-1.8%)

AUROPHARMA Share Price

Pharmaceuticals & Biotechnology

As on September 10, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 96,088 Cr

P/E Ratio27.65

Dividend Yield0.24 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,674.48	Bearish
10-DMA	1,670.35	Bearish
20-DMA	1,646.87	Bullish
50-DMA	1,607.81	Bullish
100-DMA	1,537.88	Bullish
200-DMA	1,380.71	Bullish

Historical Performance

1 Year

58.8%

3 Years

94.3%

5 Years

124.9%

10 Years

107.9%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	3,36,531	3,17,237	2,90,019	2,48,554	2,34,555
Total Expenditure	2,68,358	2,51,409	2,31,589	2,11,367	1,90,710
Other Income	5,205	6,218	5,574	2,906	3,226
Operating Profit	73,378	72,046	64,004	40,092	47,071
Interest	3,840	4,572	2,897	1,405	486
Depreciation	17,782	16,494	15,217	12,446	11,265
Profit Before Tax	51,118	50,663	43,800	26,125	33,727
Consolidated Net Profit	35,048	34,859	31,730	19,275	26,482
Adjusted EPS	60	60	54	33	45

Compounded Sales Growth

10 Years:19.5

5 Years:6.3

3 Years:6.2

TTM:1.2

Compounded Profit Growth

10 Years:11.6

5 Years:-8.1

3 Years:12.7

TTM:0.1

Stock Price CAGR

10 Years:7.6

5 Years:17.6

3 Years:24.3

TTM:50.5

Return on Equity

10 Years:39.3

5 Years:45.2

3 Years:54.2

last year:60.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	581	581	586	586	586
Total Reserves	3,78,329	3,25,952	2,97,842	2,67,813	2,45,174
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	10,967	11,627	18,089	8,669	9,031
Other Current Liabilities	58,285	44,628	31,610	29,799	31,065
Short Term Borrowings	60,796	54,702	40,781	42,304	21,178
Total Liabilities	5,70,186	4,84,920	4,38,589	3,92,125	3,36,331
Capital Work in Progress	30,088	32,660	27,394	44,964	29,376
Long Term Loans & Advances	9,716	9,734	7,146	7,940	5,753
Currents Investments	7,472	---	506	1,510	3,788
Short Term Loans and Advances	25,452	19,833	22,986	16,924	15,147
Total Current Assets	3,27,088	2,71,625	2,37,719	2,14,599	1,80,436
Total Assets	5,70,186	4,84,920	4,38,589	3,92,125	3,36,331
Adjusted Book Value	652	562	509	458	419

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 27.65, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 24.3%, indicating sustained price appreciation.
The stock carries a low beta of 0.4, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹73378 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹336531 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1504147.1

No. of Shares: 902 (Approx)

Performance:50.4%

504147.1

NIFTY Performance: -6.1%

1 day Top Gainers